z-logo
open-access-imgOpen Access
Virological failure of patients on maraviroc-based antiretroviral therapy
Author(s) -
Stéphanie Raymond,
Anne Maillard,
Corinne Amiel,
Gilles Peytavin,
MaryAnne Trabaud,
Delphine Desbois,
Pantxika Bellecave,
Constance Delaugerre,
Cathia Soulié,
AnneGeneviève Marcelin,
Diane Descamps,
Jacques Izopet,
Sandrine Reigadas,
P. Pinson-Recordon,
Hervé Fleury,
Bernard Masquelier,
A. Signori-Schmuck,
Patrice Morand,
Laurence Bocket,
L. Mouna,
Patrice André,
J. C. Tardy,
C. Charpentier,
F. Brun-Vézinet,
S. Haim-Boukobza,
A. M. Roques,
Sidonie Lambert-Niclot,
Isabelle Malet,
Marc Wirden,
S. Fourati,
Vincent Cálvez,
Philippe Flandre,
Lambert Assoumou,
Dominique Costagliola,
L. Morand-Joubert,
V. Schneider,
G. Giraudeau,
François Nicot
Publication year - 2015
Publication title -
journal of antimicrobial chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.124
H-Index - 194
eISSN - 1460-2091
pISSN - 0305-7453
DOI - 10.1093/jac/dkv026
Subject(s) - maraviroc , tropism , virology , ccr5 receptor antagonist , tissue tropism , medicine , genotyping , cxcr4 , drug resistance , population , virus , viral load , genotype , biology , microbiology and biotechnology , human immunodeficiency virus (hiv) , chemokine receptor , chemokine , genetics , gene , receptor , environmental health
Virological failure (VF) in patients on maraviroc-based treatment has been associated with altered HIV tropism and resistance to maraviroc. This multicentre study aimed to characterize VF in patients treated with maraviroc.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom